Today’s global health care crisis has highlighted how fundamental a strong medical research workforce is to our healthcare system. As the cardiovascular profession presses forward, the American College of Cardiology’s…
The Heart Failure community, including professional societies and patient advocacy organizations, have created many resources and tools to support Heart Failure patients and their caregivers. Here, you can find resources…
FARXIGA is the first SGLT2 inhibitor proven to significantly reduce the risk of cardiovascular death and hospitalization for heart failure. AstraZeneca’s FARXIGA® (dapagliflozin) has been approved in the US to reduce the…
